- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 213/56 - Amides
Patent holdings for IPC class C07D 213/56
Total number of patents in this class: 765
10-year publication summary
|
35
|
60
|
55
|
47
|
36
|
37
|
48
|
34
|
35
|
4
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4792 |
19 |
| Corteva Agriscience LLC | 2654 |
17 |
| Atnx Spv, LLC | 34 |
16 |
| Gilead Sciences, Inc. | 2145 |
14 |
| Takeda Pharmaceutical Company Limited | 2715 |
11 |
| Neurocrine Biosciences, Inc. | 437 |
10 |
| Purdue Pharma L.P. | 495 |
9 |
| The Salk Institute for Biological Studies | 450 |
8 |
| Theravance Biopharma R&D IP, LLC | 438 |
8 |
| F. Hoffmann-La Roche AG | 7879 |
7 |
| Bayer Pharma AG | 1035 |
7 |
| ACADIA Pharmaceuticals Inc. | 199 |
7 |
| CHDI Foundation, Inc. | 105 |
7 |
| Nihon Nohyaku Co., Ltd. | 331 |
7 |
| Ono Pharmaceutical Co., Ltd. | 424 |
7 |
| Tetra Discovery Partners, LLC | 11 |
7 |
| Vectus Biosystems Limited | 29 |
7 |
| Merck Sharp & Dohme LLC | 3717 |
7 |
| Hoffmann-La Roche Inc. | 3628 |
6 |
| Merck Patent GmbH | 5732 |
6 |
| Other owners | 578 |